Navigation Links
Study: Autophagy predicts which cancer cells live and die when faced with anti-cancer drugs
Date:1/10/2014

When a tumor is treated with an anti-cancer drug, some cells die and, unfortunately, some cells tend to live. A University of Colorado Cancer Center study published in the journal Nature Cell Biology details a possible difference between the susceptible and resistant cells: the rate at which cells are able to cleanse themselves via the process known as autophagy.

"In these studies, say we treat cells with the IC-50 of a drug - at that dose, 50 percent of cells should live and 50 percent of cells should die. But the fundamental question is why does cell A die whereas cell B lives? What we show is that the difference may be due to random variation in the amount of autophagy that's going on," says Andrew Thorburn, PhD, deputy director of the CU Cancer Center.

Previous studies show that autophagy promotes cell survival under conditions of stress or shortage, cells break down non-necessary components to provide energy or use the same strategy to prevent cellular damage by degrading and recycling potentially damaging proteins. And so it seems logical that cancer cells with low autophagy would have high mortality when faced with anti-cancer drugs. However, the current study shows that rates of cell death may increase or decrease depending on levels of autophagy and the specific mechanism of the anti-cancer drug.

"We separated cancer cells into populations with low and high autophagy and then treated them with two drugs, both of which should activate death. Interestingly, when treated with the first drug, cells with high autophagy had the highest mortality. But then when treated with the second drug, cells with low autophagy had the highest mortality. Depending on the drug, the effect of autophagy was opposite," Thorburn says.

Specifically, Thorburn and colleagues including first author Jacob Gump, PhD, treated high- and low-autophagy cell populations with chemicals TRAIL and Fas ligand, which activate cells' death receptors. Cells treated with these chemicals are "told" to die and as the researchers expected, some cells in all populations underwent the programmed cell death known as apoptosis. However, cells with high autophagy were more sensitive to treatment with Fas ligand, whereas cells with low autophagy were more sensitive to TRAIL. Similar differences were seen across types of cancer cells - in some cancers, autophagy protects against these drugs and in others autophagy makes cells more susceptible.

While the work does not necessarily add to our understanding of how autophagy aids cell survival, the group showed how it creates cell death in some tumors when confronted with some drugs: a protein known as FAP-1 is present in some but not all cancer cells where it serves to decrease the ability of Fas ligand to kill the cells. Autophagy degrades this cell-survival protein and this, in turn, makes cells more susceptible to Fas ligand but only in the cells where FAP-1 is normally present.

"If similar variation occurs in other contexts, a cancer cell you're trying to kill could be more or less resistant to whatever you're using to try to kill it depending on its level of autophagy," Thorburn says. Additionally, Thorburn points out that cells in these lab studies tend to be homogenous in their levels of autophagy compared to cells in natural tumor environments. It is likely, he says, these laboratory results will be magnified in actual tumors, where levels of autophagy tend to vary more widely.

While Fas ligand and TRAIL agonists are used in the lab only at this time, Thorburn says the next step in this line of research is to perform similar experiments with drugs that could be used in people.


'/>"/>
Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Study: Women not getting enough exercise; at risk of developing metabolic syndrome
2. Study: Insomnia takes toll on tinnitus patients
3. Study: No link between depression, nasal obstruction
4. Study: More Pre-Teens Get Vaccines When Middle Schools Require Them
5. Study: Kids Who Sleep in Parents Bed Less Likely to Be Overweight
6. OHSU study: Misdiagnosis of MS is costing health system millions per year
7. UW study: Sleep apnea associated with higher mortality from cancer
8. Study: Heart damage after chemo linked to stress in cardiac cells
9. STeleR study: Telerehab improves functioning after stroke
10. Study: Willingness to be screened for dementia varies by age but not by sex, race or income
11. Study: 21 percent of newly admitted nursing home residents sustain a fall during their stay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... 2017 , ... Medic CE , a Career Step company, is sponsoring ... hosted by the Journal of Emergency Medical Services (JEMS). The free webinar, to be ... by Captain Rommie Duckworth, LP, a career fire captain as well as founder and ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... prominent for-profit and nonprofit hospitals and health systems in the nation and help ... their institutions, led professional organizations and been instrumental in developing successful hospital and ...
(Date:5/23/2017)... ... , ... Axiad IDS , a leading provider of trusted identities for ... company a “Top 25 Cybersecurity Companies 2017.” Axiad IDS received this honor ... proactively address potential cybersecurity threats before they happen. The annual list of ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... and a 2017 Best in KLAS category winner, has named Daniel P. Bullington ... extend and enhance its technology platform and product offerings,” says Justin Neece, president. ...
(Date:5/23/2017)... ... May 23, 2017 , ... Drs. Allen Huang and Jeffrey ... in Las Vegas, NV, and the importance of treating it immediately. They are ... care for peri-implantitis, with or without a referral. As experienced periodontists and implant ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... , May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of ... is based on extensive data analysis from GHI,s hospitals ... hospitals database for the region. The GHI database covers 86% ... offering more than 130 data points for each institution in ...
(Date:5/9/2017)... WASHINGTON , May 9, 2017  Demonstrating ... the board of directors for the Pharmaceutical Research ... criteria for membership. Biopharmaceutical companies will now have ... in order to be eligible to join PhRMA. ... criteria, the board is sending a clear message ...
(Date:5/6/2017)... , May 5, 2017   Provista , a ... more than 200,000 customers, today announced Jim Cunniff ... wealth of executive and business experience to Provista, including most ... pharmacy in California . He assumed his ... "Jim is a great fit for Provista," says Jody ...
Breaking Medicine Technology: